Malignant pleural mesothelioma:: Clinicopathologic and survival characteristics in a consecutive series of 394 patients

被引:82
作者
Borasio, Piero
Berruti, Alfredo [1 ]
Bille, Andrea
Lausi, Paolo
Levra, Matteo Giaj [2 ]
Giardino, Roberto
Ardissone, Francesco [3 ]
机构
[1] Univ Turin, Dept Clin & Biol Sci, Med Oncol Unit, I-10124 Turin, Italy
[2] Univ Turin, Dept Clin & Biol Sci, Pulm Oncol Unit, I-10124 Turin, Italy
[3] Univ Turin, San Luigi Hosp, Dept Clin & Biol Sci, Thorac Surg Unit, I-10043 Turin, Italy
关键词
malignant pleural mesothelioma; treatment; prognosis;
D O I
10.1016/j.ejcts.2007.09.044
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Treatment of malignant pleural mesothelioma (MPM) remains disappointing, although recent reports suggest that multimodality therapy including surgery may provide a significant survival benefit. The aims of this single institution study were: to investigate clinicopathologic characteristics and potential prognostic factors in MPM patients, and to ascertain whether surgery followed by adjuvant therapy had an independent prognostic role. Methods: Retrospective review of a prospectively compiled computerized database of all patients with MPM evaluated between 1989 and 2003. Kaplan-Meier method, log-rank test, and Cox model were used in the statistical analysis. Results: There were 394 patients: 270 men (68.5%), 124 women, median age 64 (range 28-93). Twenty-seven patients (6.8%) underwent surgical resection (extrapleural pneumonectomy 15, pleurectomy/decortication 12), followed by adjuvant therapy. As of March 2006, 381 patients (96.7%) had died (median survival, 11.7 months; range 0.03-117.9). Median follow-up of 13 surviving patients (3.3%) was 45.2 months (range 28.7-126.5). Overall survival at 2 years was 18.8%. Multimodality therapy including surgery yielded a median survival of 14.5 months and a 2-year survival rate of 29.6%. Using univariate analysis, age (p = 0.009), chest pain (p = 0.01), weight toss (p = 0.001), performance status (p = 0.0001), platelet count (p = 0.008), histology (p = 0.0001), macroscopic appearance of pleural surface (non-specific inflammation, tumor-like thickening, or nodules; p = 0.0001), visceral pleura involvement (p = 0.0001), degree of involvement of pleural cavity (less than or more than one third of the cavity; p = 0.0001), and multimodality therapy (p < 0.01) were found to be significant prognostic factors. At multivariate analysis, performance status, platelet count, histology, and degree of involvement of pleural cavity remained independently associated with survival, whereas multimodality therapy failed to enter the model. Conclusions: Significant predictors of survival include performance status, platelet count, histology, and degree of involvement of pleural cavity. Within the confines of this retrospective study and the small number of patients undergoing multimodality therapy, the role of surgery in the treatment of MPM remains unclear. Further investigation is warranted to determine the optimal treatment strategy in this disease. (C) 2007 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:307 / 313
页数:7
相关论文
共 20 条
[1]  
BOUTIN C, 1993, CANCER, V72, P394, DOI 10.1002/1097-0142(19930715)72:2<394::AID-CNCR2820720214>3.0.CO
[2]  
2-5
[3]   Prognostic factors in malignant mesothelioma [J].
Burgers, JA ;
Damhuis, RAM .
LUNG CANCER, 2004, 45 :S49-S54
[4]   Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer experience [J].
Curran, D ;
Sahmoud, T ;
Therasse, P ;
van Meerbeeck, J ;
Postmus, PE ;
Giaccone, G .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) :145-152
[5]   Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems [J].
Edwards, JG ;
Abrams, KR ;
Leverment, JN ;
Spyt, TJ ;
Waller, DA ;
O'Byrne, KJ .
THORAX, 2000, 55 (09) :731-735
[6]   The pattern of lymph node involvement influences outcome after extrapleural pneumonectomy for malignant mesothelioma [J].
Edwards, JG ;
Stewart, DJ ;
Martin-Ucar, A ;
Muller, S ;
Richards, C ;
Waller, DA .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2006, 131 (05) :981-987
[7]   Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: The Memorial Sloan-Kettering experience [J].
Flores, RM .
LUNG CANCER, 2005, 49 :S71-S74
[8]   Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B [J].
Herndon, JE ;
Green, MR ;
Chahinian, AP ;
Corson, JM ;
Suzuki, Y ;
Vogelzang, NJ .
CHEST, 1998, 113 (03) :723-731
[9]   Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma [J].
Lee, TT ;
Everett, DL ;
Shu, HKG ;
Jahan, TM ;
Roach, M ;
Speight, JL ;
Cameron, RB ;
Phillips, TL ;
Chan, A ;
Jablons, DM .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2002, 124 (06) :1183-1189
[10]   Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary [J].
Maziak, DE ;
Gagliardi, A ;
Haynes, AE ;
Mackay, JA ;
Evans, WK .
LUNG CANCER, 2005, 48 (02) :157-169